← Eichor
Condition: Newly Diagnosed Ph Acute Lymphoblastic Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Newly Diagnosed Ph Acute Lymphoblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Phil
EARLY_Phase 1 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07074496Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06387121Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07493161Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom
Phase 2 · 1 location(s) · University of Washington · NCT07224100Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07564453Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06220487Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · Xijing Hospital · NCT06082934Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481228Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin
Phase 2 · 1 location(s) · University of Washington · NCT06738368A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Phase 3 · 90 location(s) · Ascentage Pharma Group Inc. · NCT06051409A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adole
Phase 2 · 155 location(s) · National Cancer Institute (NCI) · NCT06124157RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Phase 2 · 1 location(s) · Chen Suning · NCT06250959Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Phase 3 · 24 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07152041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.